Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06663319 · ClinicalTrials.gov registry record · Phase 1

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

A Phase 1 study of Colorectal Neoplasms and Gastrointestinal Neoplasms, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 1
Development phase
220
Enrollment target
9
Study locations

NCT06663319 is a Phase 1 study of Colorectal Neoplasms and Gastrointestinal Neoplasms that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 220 participants, below the 572-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (62% lower). The trial reports 9 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06663319, a Phase 1 study of Colorectal Neoplasms and Gastrointestinal Neoplasms, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 1
Development phase
220 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) of JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.

Conditions Studied

Colorectal Neoplasms Gastrointestinal Neoplasms

Interventions

  • DRUG Bevacizumab
  • DRUG FOLFIRI
  • DRUG FOLFOX
  • DRUG JNJ-89402638

Study Locations (9)

Other

  • Hosp Univ Vall D Hebron - Barcelona
  • Hosp Univ Fund Jimenez Diaz - Madrid
  • Hosp. Univ. 12 de Octubre - Madrid
  • Hosp Univ Hm Sanchinarro - Madrid

Colorado

  • University of Colorado Denver Anschultz Medical Campus - Aurora

Florida

  • Florida Cancer Specialists - Sarasota

Indiana

  • Community Health Network - Indianapolis

Michigan

  • Start Midwest - Grand Rapids

Washington

  • Swedish Cancer Institute - Seattle

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2024-10-15
Est. Completion 2028-07-19
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06663319

The ClinicalTrials.gov registry entry for NCT06663319 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 572-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (62% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Colorectal Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.

NCT06663319 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Other, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT06663319 about?

NCT06663319 is a clinical study titled "A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers". The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) of JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerabi...

What is the current status of trial NCT06663319?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2024-10-15. Estimated completion is 2028-07-19.

What conditions does trial NCT06663319 study?

This clinical trial studies the following conditions: Colorectal Neoplasms, Gastrointestinal Neoplasms.

What interventions are being tested in trial NCT06663319?

The interventions under investigation include: Bevacizumab (DRUG), FOLFIRI (DRUG), FOLFOX (DRUG), JNJ-89402638 (DRUG).

Who is sponsoring clinical trial NCT06663319?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06663319 being conducted?

This trial has 9 study locations across Colorado, Florida, Indiana, Michigan, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Neoplasms

All registered trials for this condition

Gastrointestinal Neoplasms

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.